Drug Trial Radar · NCT04699032
Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.
Last checked: Nov 19, 2026Latest source record: Oct 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Dec 8, 2020
Primary completion
Jul 5, 2021
Study completion Jul 5, 2021
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Jan 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study of pharmacokinetics and safety of apraglutide in participants with normal and impaired kidney function.
Conditions
- Chronic Kidney Disease
Interventions
ApraglutideDrug
Single dose of apraglutide 5 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of ApraglutideTime frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1
- Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) of ApraglutideTime frame: 5 minutes pre-dose up to 240 hours after dosing on Day 1
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Orlando Clinical Research Center
Orlando, Florida
Prism Clinical Research, Inc.
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.